Home
About
Overview
Sharing Data
ORCID
Help
History (55)
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Reader Response: Thrombectomy vs Medical Management for Posterior Cerebral Artery Stroke: Systematic Review, Meta-Analysis, and Real-World Data.
Novel therapeutic targets in inflammatory neuropathies
Influenza activity - United States, 2013-14 season and composition of the 2014-15 influenza vaccines.
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
See All 55 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun; 6(3):192-219.
View in:
PubMed
subject areas
Adrenal Cortex Hormones
Aminosalicylic Acids
Anti-Bacterial Agents
Humans
Immunosuppressive Agents
Inflammatory Bowel Diseases
Sulfasalazine
authors with profiles
Stephen B. Hanauer